First-line sunitinib plus FOLFIRI in Japanese patients with unresectable/metastatic colorectal cancer: A phase II study

Cancer Science

Volumn 103, Issue 8, 2012, Pages 1502-1507

  Tsuji, Yasushi ^a   Satoh, Taroh ^b   Tsuji, Akihito ^c   Muro, Kei ^d   Yoshida, Motoki ^e   Nishina, Tomohiro ^f   Nagase, Michitaka ^g   Komatsu, Yoshito ^h   Kato, Takeshi ⁱ   Miyata, Yoshinori ^j   Mizutani, Naoko ^k   Hashigaki, Satoshi ^k   Lechuga, Maria Jose ^k   Denda, Tadamichi ^b  

^a Tonan Hospital   (Japan)

^b KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c Kochi Health Sciences Center   (Japan)

^d AICHI CANCER CENTER HOSPITAL   (Japan)

^e OSAKA MEDICAL COLLEGE HOSPITAL   (Japan)

^f NATIONAL HOSPITAL ORGANIZATION SHIKOKU CANCER CENTER   (Japan)

^g JICHI MEDICAL UNIVERSITY   (Japan)

^h HOKKAIDO UNIVERSITY HOSPITAL   (Japan)

ⁱ Minoh City Hospital   (Japan)

^j Nagano Prefectural Federation of Agricultural Cooperative for Health and Welfare   (Japan)

^k PFIZER INC   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; FOLINIC ACID; IRINOTECAN; SUNITINIB;

ADULT; ADVERSE OUTCOME; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ALOPECIA; ANEMIA; APPETITE; APPETITE DISORDER; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER SURVIVAL; COLORECTAL CANCER; CONSTIPATION; DIARRHEA; DYSGEUSIA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; JAPANESE; LEUKOPENIA; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; METASTASIS; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SIDE EFFECT; SKIN DISCOLORATION; STOMATITIS; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASIAN CONTINENTAL ANCESTRY GROUP; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; HUMANS; INDOLES; LEUCOVORIN; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PYRROLES; TREATMENT OUTCOME;

EID: 84864292535     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2012.02320.x     Document Type: Article

References (24)

1. Goodwin RA, Asmis TR. Overview of systemic therapy for colorectal cancer. Clin Colon Rectal Surg 2009; 22: 251-6.
2. Abrams TJ, Lee LB, Murray LJ, Pryer NK, Cherrington JM. SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther 2003; 2: 471-8.
3. Kim DW, Jo YS, Jung HS et al. An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases. J Clin Endocrinol Metab 2006; 91: 4070-6.
4. Mendel DB, Laird AD, Xin X et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003; 9: 327-37.
5. Murray LJ, Abrams TJ, Long KR et al. SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model. Clin Exp Metastasis 2003; 20: 757-66.
6. O'Farrell AM, Abrams TJ, Yuen HA et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 2003; 101: 3597-605.
7. Kodera Y, Katanasaka Y, Kitamura Y et al. Sunitinib inhibits lymphatic endothelial cell functions and lymph node metastasis in a breast cancer model through inhibition of vascular endothelial growth factor receptor 3. Breast Cancer Res 2011; 13: R66.
8. ® (sunitinib) prescribing information. [Cited 4 Feb 2011.] Available from URL:.
9. Raymond E, Dahan L, Raoul JL et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011; 364: 501-13.
10. Saltz LB, Rosen LS, Marshall JL et al. Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy. J Clin Oncol 2007; 25: 4793-9.
11. Starling N, Vázquez F, Cunningham D et al. A phase I study of sunitinib in combination with FOLFIRI in patients with untreated metastatic colorectal cancer. Ann Oncol 2011; 23: 119-27.
12. Carrato A, Swieboda-Sadlej A, Staszewska-Skurczynska M et al. Final results from a randomized double-blind phase III study of sunitinib plus FOLFIRI vs. placebo plus FOLFIRI in first-line treatment of patients (pts) with metastatic colorectal cancer (MCRC) (abstract). Ann Oncol 2010; 21: O-0026.
13. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92: 205-16.
14. Tournigand C, Andre T, Achille E et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004; 22: 229-37.
15. Fuse N, Doi T, Ohtsu A et al. Safety of irinotecan and infusional fluorouracil/leucovorin (FOLFIRI) in Japan: a retrospective review of 48 patients with metastatic colorectal cancer. Int J Clin Oncol 2008; 13: 144-9.
16. Okuyama Y, Hazama S, Nozawa H et al. Prospective phase II study of FOLFIRI for mCRC in Japan, including the analysis of UGT1A1*28/*6 polymorphisms. Jpn J Clin Oncol 2011; 41: 477-82.
17. Sunakawa Y, Ichikawa W, Fujita KI et al. UGT1A1*1/*28 and *1/*6 genotypes have no effects on the efficacy and toxicity of FOLFIRI in Japanese patients with advanced colorectal cancer. Cancer Chemother Pharmacol 2011; 68: 279-84.
18. Takahari D, Tsuji Y, Tanaka S et al. [Feasibility of modified FOLFIRI regimen for patients with refractory advanced or recurrent colorectal cancer]. Gan To Kagaku Ryoho 2007; 34: 207-11.
19. Yukawa N, Yamamoto Y, Akaike M et al. [Modified FOLFIRI (l-LV, 5-fluorouracil and irinotecan) therapy for Japanese patients with metastatic colorectal cancer]. Gan To Kagaku Ryoho 2010; 37: 1291-5.
20. Sobrero A, Ackland S, Clarke S et al. Phase IV study of bevacizumab in combination with infusional fluorouracil, leucovorin and irinotecan (FOLFIRI) in first-line metastatic colorectal cancer. Oncology 2009; 77: 113-9.
21. Matsumoto R, Kuroda T, Yamada H, Hasegawa K, Mamiya Y, Kon A. [Chemotherapy with bevacizumab (BV) + modified FOLFOX6 for unresectable colorectal cancer]. Gan To Kagaku Ryoho 2009; 36: 2207-9.
22. Houk BE, Bello CL, Poland B, Rosen LS, Demetri GD, Motzer RJ. Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis. Cancer Chemother Pharmacol 2010; 66: 357-71.
23. Hamaguchi T, Yoshino T, Ohtsu A et al. Phase I study of first-line sunitinib plus modified FOLFOX6 (mFOLFOX6) in Japanese patients with metastatic colorectal cancer. ECCO 15-34th ESMO Multidisciplinary Congress, September 20-24, 2009 (Abstract 6063).
24. Ishida H, Fujita KI, Akiyama Y et al. Regimen selection for first-line FOLFIRI and FOLFOX based on UGT1A1 genotype and physical background is feasible in Japanese patients with advanced colorectal cancer. Jpn J Clin Oncol 2011; 41: 617-23.